Methionine aminopeptidase-2 (METAP2) inhibitors have demonstrated potent antiangiogenic and antitumor effects in patients with late-stage cancer (1–3) as well as highly favorable metabolic effects, including significant weight loss and improvements in insulin sensitivity and blood lipid levels in obese patients (4, 5). The gene discussed is INS; the disease is cancer.